Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU‐285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignancies-Reference-Cited by-同舟云学术

Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU‐285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignancies

Published:2019-07-15 Issue:4 Volume:187 Page:488-501
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Weisberg Ellen¹²^ORCID,Meng Chengcheng¹,Case Abigail E.¹,Sattler Martin¹²,Tiv Hong L.³,Gokhale Prafulla C.³,Buhrlage Sara J.⁴,Liu Xiaoxi⁴,Yang Jing⁴,Wang Jinhua⁵,Gray Nathanael⁵,Stone Richard M.¹²,Adamia Sophia¹²,Dubreuil Patrice⁶,Letard Sebastien⁶,Griffin James D.¹²

Affiliation:

1. Department of Medical Oncology Dana‐Farber Cancer Institute BostonMAUSA

2. Department of Medicine Harvard Medical School BostonMAUSA

3. Experimental Therapeutics Core and Belfer Center for Applied Cancer Science Dana‐Farber Cancer Institute, Harvard Medical School BostonMAUSA

4. Department of Cancer Biology Dana‐Farber Cancer Institute, Harvard Medical School BostonMAUSA

5. Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School Boston MA USA

6. CRCM, [Signalling, Haematopoiesis and Mechanism of Oncogenesis, Equipe Labellisée Ligue Contre le Cancer] Inserm, U1068; Institut Paoli‐Calmettes; Aix‐Marseille University Marseille France

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.16092

Reference61 articles.

1. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib

2. Prognostic relevance of FLT3-TKD mutations in AML: the combination matters—an analysis of 3082 patients

3. Emergence of Polyclonal FLT3 Tyrosine Kinase Domain Mutations during Sequential Therapy with Sorafenib and Sunitinib in FLT3-ITD–Positive Acute Myeloid Leukemia

4. Two cell lines of t(8;21) acute myeloid leukemia with activating KIT exon 17 mutation: models for the ‘second hit’ hypothesis

5. Prediction of Resistance to Small Molecule FLT3 Inhibitors

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Investigations on druggable gene mutations related to AML/ALL lineage genes in Advanced Phases of CML: Implications in patient-tailored therapy of blast crisis CML in TKI era;2024-09-09

2. Precision medicine in AML: overcoming resistance;International Journal of Hematology;2024-08-01

3. Ningetinib, a novel FLT3 inhibitor, overcomes secondary drug resistance in acute myeloid leukemia;Cell Communication and Signaling;2024-07-08

4. Phase 1 study of azacitidine in combination with quizartinib in patients with FLT3 or CBL mutated MDS and MDS/MPN;Leukemia Research;2024-07

5. Application of omics in the diagnosis, prognosis, and treatment of acute myeloid leukemia;Biomarker Research;2024-06-10